ASCC2 and cancer: Moreover, we observed that a large number of ASCC2 and ASCC3 residue substitutions encoded by somatic mutations in cancers map to ASCC2–ASCC3 interface regions and that selected, cancer-related residue substitutions in ASCC3 lead to reduced ASCC2–ASCC3 affinity.